No abstract available

No abstract available

[en] The book contains reports of areas of growth in radiation oncology written for the practising radiation oncologist. Early chapters review conservative treatments that preserve the function and maintain or improve tumor control rates in breast, rectum, anus, head and neck, soft tissues and bones, and the eye. This is followed by a section dealing with extended field therapy encompassing total body irradiation, half body irradiation and systemic therapy with radionuclide-labelled antibodies. The potential roles of three new diagnostic imaging technologies (CT, MRI and PET) in radiotherapy are considered. Various modifications of treatment are reviewed, including hyperfractionation, accelerated treatment, accelerated hyperfractionation and neutron therapy. Also discussed is the clinical use of adjuvants to radiotherapy, such as radiosensitizers, cytotoxic drugs, interstitial and external hyperthermia and bone fixation in metastatic disease

[en] Conventional radiotherapy uses multiple fractional doses each of which is small enough that cell killing occurs predominantly through ''single events''. If cellular survival from each fraction were plotted on a single dose-survival curve, it would be within the shoulder region. The initial slope, and the dose range over which survival begins decreasing more rapidly due to lethality from accumulated sublethal events, are the dose-survival parameters most relevant to radiotherapy. Several methods are used to quantify the response of tissues to doses in the range used clinically. At present, such dose-response parameters are subject to considerable uncertainty, but at least they provide a basis for improved understanding of tissue responses to radiation and a framework for further experimentation and, ultimately, for selecting optimum-sized dose fractions

No abstract available

[en] This book contains the proceedings of a symposium held in February and March 1979. The publication of the book in early 1980 represents a timely appearance of the 40 scientific presentations and conference summary from a rather large meeting. The papers are organized into six categories ranging from basic biophysics of radiation damage to new methods and combinations in radiation therapy of human malignancies. This organization, going from the basic mechanisms of radiation damage to new therapy applications, is a logical one, and the relatively large emphasis on papers in the first category is a refreshing change for a symposium of this sort. The quality of editing, production, and illustrations is high

[en] This study was supported in part by the Department of Health, Education, and Welfare, National Institutes of Health, National Cancer Institutegrants CA-11138 and Ca-12542. 1. Increasing the size of dose fractions (by reducing the number used in a course of radiotherapy) will increase late injury relative to acute responses and may also reduce the therapeutic ratio. Therefore, if neutrons are available for only 2 or 3 days per week, it may be advantageous to treat patients with X- or γ-rays in intervening days to ensure the use of 5 fractions per week. 2. The RBE sub(n/γ) which is relevant to radiotherapy is that measured at 200 rads of γ-rays. The total neutron dose should then be the amount of total x- or γ-ray dose divided by RBE sub(n/γ). 3. The total neutron dose may be divided into various numbers of dose fractions; but, in general, the more the better. Unlike changes in γ-ray dose-fractionation, changes in neutron dose fractionation do not require changes in total dose. (Evans, J.)

[en] This edited collection divides the subject matter into the following categories: The problem of radioresistance; Normal tissue radioresistance; Therapeutic approaches to radioresistance

No abstract available

[en] Three indirect methods have been used to estimate the response of 4 normal tissues of mice to low doses of γ-irradiation. Survival curves of cells of tissues studied (stomach, thin intestine, spermatic and blood-forming stem cells) are exponential in the dose range from 0 to 100-230 rad, the slope being 1/3 from that at large doses. The uncertainty of the data obtained somehow reflects variations in the distribution of cells over cycle phases